Biohaven Pharmaceutical Holding (BHVN) PT Raised to $165 at Cowen

Cowen analyst Ken Cacciatore raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $165.00 (from $140.00) while maintaining a Outperform rating.

The analyst commented, "Nurtec Q3 revenues have reached $136MM (+46% Q/Q), nicely above the Street's $110MM, and importantly, the net value per Rx continues to strengthen, now at $455 (+5% Q/Q), which nicely complemented the likely prevention-driven inflecting Rx growth. Nurtec continues to validate our views of the product's likely ultimate size and we believe investors need to begin to contemplate the ex-US value. Add."

You May Also Be Interested In

• Energy Fuels (UUUU) PT Raised to $29.25 at H.C. Wainwright
• BofA Securities Upgrades Timken (TKR) to Buy, 'Early innings of a transformation story'
• Piper Sandler Upgrades Tempus AI Inc (TEM) to Overweight, 'On A Train Back To Upside, We're Not Jumping the Gun'